Advanced Accelerator Applications S.A. (NASDAQ:AAAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The brokerage presently has a $44.00 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 11.00% from the stock’s current price.

According to Zacks, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France. “

Other analysts have also issued research reports about the stock. Jefferies Group LLC reiterated a “buy” rating and set a $50.00 price target on shares of Advanced Accelerator Applications in a research report on Friday, March 24th. Canaccord Genuity set a $47.00 price objective on shares of Advanced Accelerator Applications and gave the company a “buy” rating in a research note on Wednesday, May 31st. TheStreet raised shares of Advanced Accelerator Applications from a “d” rating to a “c-” rating in a research note on Thursday, March 23rd. BidaskClub raised shares of Advanced Accelerator Applications from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, J P Morgan Chase & Co assumed coverage on shares of Advanced Accelerator Applications in a research note on Thursday, June 15th. They issued an “overweight” rating and a $50.00 price objective for the company. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $47.75.

Advanced Accelerator Applications (AAAP) traded up 0.39% on Tuesday, hitting $39.64. 55,423 shares of the stock were exchanged. Advanced Accelerator Applications has a 1-year low of $23.50 and a 1-year high of $40.92.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/11/advanced-accelerator-applications-s-a-nasdaqaaap-rating-increased-to-buy-at-zacks-investment-research.html.

A number of institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new position in shares of Advanced Accelerator Applications during the first quarter valued at approximately $160,000. Geode Capital Management LLC increased its position in shares of Advanced Accelerator Applications by 32.6% in the first quarter. Geode Capital Management LLC now owns 22,095 shares of the company’s stock valued at $880,000 after buying an additional 5,438 shares during the last quarter. Birchview Capital LP bought a new position in shares of Advanced Accelerator Applications during the first quarter valued at approximately $279,000. KCG Holdings Inc. bought a new position in shares of Advanced Accelerator Applications during the first quarter valued at approximately $338,000. Finally, A.R.T. Advisors LLC bought a new position in shares of Advanced Accelerator Applications during the fourth quarter valued at approximately $334,000. 40.91% of the stock is owned by institutional investors and hedge funds.

Advanced Accelerator Applications Company Profile

Advanced Accelerator Applications SA is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.

Get a free copy of the Zacks research report on Advanced Accelerator Applications (AAAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Advanced Accelerator Applications (NASDAQ:AAAP)

Receive News & Ratings for Advanced Accelerator Applications S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications S.A. and related companies with MarketBeat.com's FREE daily email newsletter.